fosun pharma net profit for shareholders after deducting non-recurring gains and losses up 21.73% in q1 2022 continues development of innovative products
during the reporting period, benefited from the growth of comirnaty® (mrna covid-19 vaccine), han qu you (trastuzumab injection), su ke xin (avatrombopag maleate tablets), heparin series preparations and other products, in the first quarter of 2022, fosun pharma achieved revenue of rmb10,382 million, representing an increase of 28.87% yoy; the net profit for shareholders after deducting non-recurring gains and losses amounted to rmb801 million, representing an increase of rmb143 million or an increase of 21.73% yoy.
continues promoting the r&d, registration and commercialization of innovative products
in the first quarter of 2022, fosun pharma continued to promote the development and implementation of innovative products and technologies. in march 2022, han si zhuang (serplulimab injection) independently developed by fosun pharma received conditional approval for launch by the national medical products administration (‘‘nmpa’’) as the treatment of adult patients with advanced unresectable or metastatic microsatellite instability-high (the ‘‘msi-h’’) solid tumors. it had entered the clinical application stage in medical institutions in jiangsu, tianjin, zhejiang, guangdong, hunan, beijing and other regions. in addition, in april 2022, the drug registration application in chinese mainland (excluding hong kong, macau and taiwan region) for using han si zhuang (serplulimab injection) in combination with chemotherapy for the first-line treatment of extensive-stage small-cell lung cancer (es-sclc) was accepted, and the orphan-drug designation in respect of using han si zhuang (serplulimab injection) for the treatment of small-cell lung cancer (sclc) was granted by the food and drug administration (‘‘fda’’) of the united states.
in march 2022, fosun kite, a joint venture, received approval from the nmpa to initiate clinical trials of its second car-t cell therapy product fkc889 for the treatment of adult patients with relapsed or refractory indolent non-hodgkin lymphoma (r/r inhl) after two or more lines of systemic therapy.
in february 2022, fosun pharma’s biopharmaceutical platform henlius has entered into a licensing and supply agreement with getz pharma granting a license for getz pharma to exclusively commercialize han da yuan (adalimumab injection) in 11 emerging markets in asia, africa and europe, as to further expand overseas markets.
supporting the fight against covid-19 actively and accelerating the deployment of anti-epidemic related products
during the reporting period, fosun pharma actively responded to local epidemic prevention and control policies and supported the fight against the epidemic. fosun pharma has continuously supplied comirnaty® (mrna covid-19 vaccine) to hong kong sar, macau sar and taiwan region. as of the end of march 2022, more than 24 million doses of bnt162b2 vaccine have been administrated in hong kong sar, macau sar and taiwan region.
moreover, in the first quarter of 2022, fosun pharma obtained the medicines patent pool (mpp)'s license to produce and supply the generic version of merck's oral covid-19 treatment molnupiravir and pfizer’s oral covid-19 treatment nirmatrelvir, as well as the co-packaged product of nirmatrelvir and ritonavir of pfizer, to agreed low- and middle-income countries. the license includes both ingredients and the finished drug. as a global innovation-driven pharmaceutical and healthcare industry group, fosun pharma implements its internationalization strategy in multiple dimensions including innovative r&d, bd, production, operation and commercialization. it is committed to improving the accessibility and affordability of covid-19 treatments in low- and middle-income countries worldwide and will continue to contribute to the global pandemic response to covid-19 and help save more lives.
in march 2022, fosun pharma's mobile cabin laboratory officially started testing and became the first mobile cabin laboratory with all three certificates in shanghai, actively helping to prevent and control the epidemic in shanghai. in april 2022, fosun pharma’s self-developed novel coronavirus (2019-ncov) antigen detection kit (colloidal gold) was also been approved in the chinese mainland. previously, the product has obtained the eu ce certification, duly completed bfarm registration in germany, and was officially endorsed by the eu health security committee common list (eu common list).
founded in 1994, shanghai fosun pharmaceutical (group) co., ltd. ("fosun pharma"; stock code: 600196. sh, 02196. hk) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in china. fosun pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. as a shareholder of sinopharm co., ltd., fosun pharma expands its areas in the pharmaceutical distribution and retail business.
fosun pharma is patient-centered and clinical needs-oriented. the company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. fosun pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, and central nervous system. fosun pharma also vigorously explores cutting-edge technologies, such as rna, oncolytic viruses, gene therapy and protac, to enhance its innovation capabilities.
guided by the 4in strategy (innovation, internationalization, integration, and intelligentization), fosun pharma will uphold the development model of “innovation transformation, integrated operation, and steady growth", with the mission of creating shareholder values as well as promoting the global networks through strengthening its innovative r&d and in-licensing ability and enriching its product pipelines. fosun pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global mainstream medical and health market.
for more information, please visit our official website: www.fosunpharma.com.
fosun pharma forward-looking statements
this press release contains forward-looking statements. all statements other than statements of historical fact contained in this press release, including, without limitation, the discussions of fosun pharma’s business strategies and expectations concerning future operations, margins, profitability, liquidity and capital resources, the future development of fosun pharma’s industry and the future development of the general economy of fosun pharma’s key markets and any statements preceded by, followed by or that include words and expressions such as “expect”, “seek”, “believe”, “plan”, “intend”, “estimate”, “project”, “anticipate”, “may”, “will”, “would” and “could” or similar words or statements, as they relate to fosun pharma’s or its management, are intended to identify forward-looking statements. these statements are subject to certain known and unknown risks, uncertainties and assumptions, which may cause fosun pharma’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. accordingly, you should not place undue reliance on any forward-looking information. subject to the requirements of applicable laws, rules and regulations, fosun pharma does not have any and undertakes no obligation to update or otherwise revise the forward- looking statements in this press release, whether as a result of new information, future events or developments or otherwise. in this press release, statements of or references to fosun pharma’s intentions are made as of the date of this press release. any such intentions may change in light of future developments. all forward-looking statements contained in this press release are qualified by reference to the cautionary statements set out above.